Cost-effectiveness of 2009 Pandemic Influenza A(H1N1) Vaccination in the United States

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Aug 11

PMID 21829456

Citations 20

Authors

Lisa A Prosser

Tara A Lavelle

Anthony E Fiore

Carolyn B Bridges

Carrie Reed

Seema Jain

Kelly M Dunham

Martin I Meltzer

Affiliations

Soon will be listed here.

Abstract

Background: Pandemic influenza A(H1N1) (pH1N1) was first identified in North America in April 2009. Vaccination against pH1N1 commenced in the U.S. in October 2009 and continued through January 2010. The objective of this study was to evaluate the cost-effectiveness of pH1N1 vaccination.

Methodology: A computer simulation model was developed to predict costs and health outcomes for a pH1N1 vaccination program using inactivated vaccine compared to no vaccination. Probabilities, costs and quality-of-life weights were derived from emerging primary data on pH1N1 infections in the US, published and unpublished data for seasonal and pH1N1 illnesses, supplemented by expert opinion. The modeled target population included hypothetical cohorts of persons aged 6 months and older stratified by age and risk. The analysis used a one-year time horizon for most endpoints but also includes longer-term costs and consequences of long-term sequelae deaths. A societal perspective was used. Indirect effects (i.e., herd effects) were not included in the primary analysis. The main endpoint was the incremental cost-effectiveness ratio in dollars per quality-adjusted life year (QALY) gained. Sensitivity analyses were conducted.

Results: For vaccination initiated prior to the outbreak, pH1N1 vaccination was cost-saving for persons 6 months to 64 years under many assumptions. For those without high risk conditions, incremental cost-effectiveness ratios ranged from $8,000-$52,000/QALY depending on age and risk status. Results were sensitive to the number of vaccine doses needed, costs of vaccination, illness rates, and timing of vaccine delivery.

Conclusions: Vaccination for pH1N1 for children and working-age adults is cost-effective compared to other preventive health interventions under a wide range of scenarios. The economic evidence was consistent with target recommendations that were in place for pH1N1 vaccination. We also found that the delays in vaccine availability had a substantial impact on the cost-effectiveness of vaccination.

Citing Articles

Respiratory Syncytial Virus Sequelae Among Adults in High-Income Countries: A Systematic Literature Review and Meta-analysis.

Ubamadu E, Betancur E, Gessner B, Menon S, Vroling H, Curcio D Infect Dis Ther. 2024; 13(7):1399-1417.

PMID: 38789901 PMC: 11219677. DOI: 10.1007/s40121-024-00974-7.

Lessons from past pandemics: a systematic review of evidence-based, cost-effective interventions to suppress COVID-19.

Juneau C, Pueyo T, Bell M, Gee G, Collazzo P, Potvin L Syst Rev. 2022; 11(1):90.

PMID: 35550674 PMC: 9096744. DOI: 10.1186/s13643-022-01958-9.

The Use of Expert Elicitation among Computational Modeling Studies in Health Research: A Systematic Review.

Cadham C, Knoll M, Sanchez-Romero L, Cummings K, Douglas C, Liber A Med Decis Making. 2021; 42(5):684-703.

PMID: 34694168 PMC: 9035479. DOI: 10.1177/0272989X211053794.

Natural outbreaks and bioterrorism: How to deal with the two sides of the same coin?.

Koch L, Lopes A, Maiguy A, Guillier S, Guillier L, Tournier J J Glob Health. 2020; 10(2):020317.

PMID: 33110519 PMC: 7535343. DOI: 10.7189/jogh.10.020317.

Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.

Crepey P, Boiron L, Araujo R, Lopez J, Petitjean A, Luna E BMC Public Health. 2020; 20(1):1374.

PMID: 32907562 PMC: 7487874. DOI: 10.1186/s12889-020-09409-7.

References

. Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep. 2009; 58(17):467-70. View

Yang Y, Sugimoto J, Halloran M, Basta N, Chao D, Matrajt L . The transmissibility and control of pandemic influenza A (H1N1) virus. Science. 2009; 326(5953):729-33. PMC: 2880578. DOI: 10.1126/science.1177373. View

Coleman M, Fontanesi J, Meltzer M, Shefer A, Fishbein D, Bennett N . Estimating medical practice expenses from administering adult influenza vaccinations. Vaccine. 2004; 23(7):915-23. DOI: 10.1016/j.vaccine.2004.07.028. View

Baguelin M, van Hoek A, Jit M, Flasche S, White P, Edmunds W . Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. Vaccine. 2010; 28(12):2370-84. DOI: 10.1016/j.vaccine.2010.01.002. View

. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep. 2009; 58(16):433-5. View

Shrestha S, Swerdlow D, Borse R, Prabhu V, Finelli L, Atkins C . Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis. 2011; 52 Suppl 1:S75-82. DOI: 10.1093/cid/ciq012. View

Fiore A, Uyeki T, Broder K, Finelli L, Euler G, Singleton J . Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010; 59(RR-8):1-62. View

Schonberger L, Bregman D, Sullivan-Bolyai J, Keenlyside R, ZIEGLER D, Retailliau H . Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol. 1979; 110(2):105-23. DOI: 10.1093/oxfordjournals.aje.a112795. View

Miller M, Viboud C, Olson D, Grais R, Rabaa M, Simonsen L . Prioritization of influenza pandemic vaccination to minimize years of life lost. J Infect Dis. 2008; 198(3):305-11. PMC: 3206321. DOI: 10.1086/589716. View

10.

Keren R, Zaoutis T, Saddlemire S, Luan X, Coffin S . Direct medical cost of influenza-related hospitalizations in children. Pediatrics. 2006; 118(5):e1321-7. DOI: 10.1542/peds.2006-0598. View

11.

Nichol K . The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine. 2003; 21(16):1769-75. DOI: 10.1016/s0264-410x(03)00070-7. View

12.

Lee B, Brown S, Cooley P, Zimmerman R, Wheaton W, Zimmer S . A computer simulation of employee vaccination to mitigate an influenza epidemic. Am J Prev Med. 2010; 38(3):247-57. PMC: 2833347. DOI: 10.1016/j.amepre.2009.11.009. View

13.

Goldie S, Kohli M, Grima D, Weinstein M, Wright T, Bosch F . Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96(8):604-15. DOI: 10.1093/jnci/djh104. View

14.

. Update: swine influenza A (H1N1) infections--California and Texas, April 2009. MMWR Morb Mortal Wkly Rep. 2009; 58(16):435-7. View

15.

Safranek T, Lawrence D, Kurland L, Culver D, Wiederholt W, HAYNER N . Reassessment of the association between Guillain-Barré syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol. 1991; 133(9):940-51. DOI: 10.1093/oxfordjournals.aje.a115973. View

16.

Lasky T, Terracciano G, Magder L, Koski C, Ballesteros M, Nash D . The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998; 339(25):1797-802. DOI: 10.1056/NEJM199812173392501. View

17.

Parkin W, Beecham H, Streiff E, Sharrar R, Harris J . Relationship studied in Pennsylvania. Guillain-Barré syndrome and influenza immunization. Pa Med. 1978; 81(4):47-8, 50-2. View

18.

. Update: infections with a swine-origin influenza A (H1N1) virus--United States and other countries, April 28, 2009. MMWR Morb Mortal Wkly Rep. 2009; 58(16):431-3. View

19.

. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009; 58(RR-10):1-8. View

20.

. Swine-origin influenza A (H1N1) virus infections in a school - New York City, April 2009. MMWR Morb Mortal Wkly Rep. 2009; 58(17):470-2. View